Skip to content

Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy

Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy - a Randomized Controlled Trial. THE MINIMUM STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03631173
Acronym
MINIMUM
Enrollment
201
Registered
2018-08-15
Start date
2019-04-02
Completion date
2028-06-30
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Cancer, Duodenal Cancer, Pancreatic Cancer, Pancreatic Fistula, Pancreatic Neoplasms

Keywords

Pancreaticoduodenectomy, Pancreatectomy, Anastomosis, Surgical

Brief summary

A pancreaticoduodenectomy is performed in patient with pancreatic cancer. The most common and serious complication is leakage between the intestine and the remnant pancreas after this procedure. It occurs in 20-30%. The result is often prolonged hospital and ICU stay, reoperations and deaths (3-5%). To detect a leakage early before the patient becomes seriously ill, thereby initiating treatment is therefore very important. By inserting a thin microdialysis catheter near the anastomosis between pancreas and intestine before closure of the abdominal wall, the investigators will analyze substances such as lactic acid, pyruvate, glycerol, etc. and if these substances may reveal anastomosis leakage at an early stage. Observational studies have shown that if a leakage occurs, glycerol concentration in the microdialysate will rise significant after few hours, and changes in lactic acid and pyruvate values will change as a sign of inflammation. The investigators want to conduct a randomized study comparing patients undergoing pancreaticoduodenectomy and using microdialysis in half of the included population.

Detailed description

Anastomotic leakage after pancreaticoduodenectomy is a feared complication with substantial mortality and morbidity. Treatment of a postoperative pancreatic fistula can be difficult and management may range from a simple observation with or without percutaneous drainage, to the urgent need for reoperation and management of abdominal sepsis with organ failure and prolonged intensive care. To diagnose a pancreatic fistula may have a delay of several days. The risk of death and severe morbidity raises considerable from a biochemical pancreatic fistula compared to the most serious form, a grade C. Also, the cost of managing a patient with a fistula is 1.3-6 times more than a patient with no complications after PD. Microdialysis is a promising tool in patients who undergoes pancreaticoduodenectomy for early detection of postoperative pancreatic fistula development. The technique may reveal an fistula before severe symptoms occur and before the complication gives the patient serious and life-threatening symptoms. Earlier intervention of the postoperative pancreatic fistula may lead to better prognosis, less reoperations and interventions and shorter stay at the ICU/hospital. By monitoring intraperitoneal metabolites (glycerol, lactate, pyruvate and glucose) close to the pancreaticojejunostomy, signs of a leakage may be discovered in few hours, thereby make it possible for early intervention and prevent developement of serious progression of morbidity. The investigators want to perform a randomized study where half of the patients will receive a microdialysis catheter implanted close to the pancreaticoduodenal anastomosis before closure of the abdomen. At certain timepoints postoperatively microdialysate will be analyzed for glycerol, lactate, pyruvate and glucose and the data will be used in the decisionmaking of diagnosing a pancreatic anastomosis leakage in addition to standard management. The other half of the patients will not receive a microdialysis catheter and the decisionmaking will only be based on standard management (ie. inflammation markers in blood samples, amylase in drainage fluid).

Interventions

PROCEDURESurgical og radiological intervention, antibiotics

Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

2-armed, multicenter, randomized, open label, parallel-group controlled trial (RCT)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must be scheduled for a pancreaticoduodenectomy * Subject must be ≥ 18 years * Able to give written signed informed consent * Investigator's assessment that the patient is able to understand, comply and follow the instructions needed to successfully participate in this trial

Exclusion criteria

* Allergic to Voluven® (Fresenius Kabi AS, Halden, Norway) and contrast given during CT scan * Another study interfering with current study * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
Total hospital stay30 days after surgery - postoperative day 30Number of days from end of surgery to hospital discharge (at any hospital)

Secondary

MeasureTime frameDescription
Length of stay at the primary hospital30 days after surgery - postoperative day 30Length of stay at the primary hospital and ICU. Number of days from initial operation to primary hospital discharge.
Concentration of Lactate (mM), Pyruvate (microM), Glycerol (microM), Glucose (mM) in microdialysate30 days after surgery - postoperative day 30Concentration of Lactate, Pyruvate, Glycerol, Glucose in microdialysate in relation to patients with or without anastomosis leakage
Concentration of inflammatory markers in microdialysate30 days after surgery - postoperative day 30Concentration of inflammatory markers in microdialysate in relation to patients with or without anastomosis leakage
Concentration of inflammatory markers in serum30 days after surgery - postoperative day 30Concentration of inflammatory markers in serum in relation to patients with or without anastomosis leakage
Patient-reported quality of life questionnaire - total score assessed by the Abdominal surgery Impact scale by summing subscoresFrom inclusion to 90-days after surgeryTotal score - Abdominal surgery Impact scale. The summative scores for the scale range from 18 to 126, with higher scores indicating better quality of life
Patient-reported quality of life questionnaire - subgroup score Physical limitations assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Physical limitations - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better physical ability
Patient-reported quality of life questionnaire - subgroup score Functional impairment assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Functional impairment - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better functional ability
Patient-reported quality of life questionnaire - subgroup score Pain assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Pain - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more pain
Patient-reported quality of life questionnaire - subgroup score Visceral Function assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Visceral Function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more Visceral dysfunction
Patient-reported quality of life questionnaire - subgroup score Sleep assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Sleep - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more sleep dysfunction
Patient-reported quality of life questionnaire - subgroup score Psychological function assessed by the Abdominal surgery Impact scaleFrom inclusion to 90-days after surgerySubgroup score Psychological function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more psychological dysfunction
Patient-reported pain questionnaire - total score assessed by the McGill Pain Questionnaire-2 (SF-MPQ-2)From inclusion to 90-days after surgeryTotal score - McGill Pain Questionnaire-2 (SF-MPQ-2). Subgroup score Psychological function - Abdominal surgery Impact scale. The summative scores ranging from 0 to 45, with higher score indicating more pain
Expenses (Euros) per patient used during total hospital stay30 days after surgery - postoperative day 30Number of Euros used in patient undergoing pancreaticoduodenectomy With or without microdialysis catheter
Daily assessement of microdialysis catheter malfunction during admission at hospital, at an average of 10 days after surgeryFrom surgery end to discharge from primary hospital, at an average of 10 days after surgeryNumber of catheter which are not functioning
Risk factors of postoperative pancreatic fistula at discharge from hospital, at an average 10 days after surgeryFrom surgery end to discharge from primary hospital at hospital, at an average of 10 days after surgeryNumbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Risk factors of postoperative pancreatic fistula at 30 days after surgeryFrom surgery end to 30 days after surgeryNumbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Risk factors of postoperative pancreatic fistula at 90 days after surgeryFrom surgery end to 90 days after surgeryNumbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage

Countries

Norway

Contacts

PRINCIPAL_INVESTIGATOREspen Lindholm, ph.d

Oslo University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026